The SIP Index released the 2021Q3 pharmaceutical industry development index 128, and the industry's overall profit increased by 67% year-on-year

At a major turning point in industrial development, with the purpose of promoting the high-quality development of China's health industry, Zhongkang Technology released the chypre index for the first time at the 2021 chypre meeting
.

Based on a wide range of industry data accumulation and standardized evaluation models, the SIP index comprehensively, intuitively, objectively and rigorously evaluates the development status of the pharmaceutical industry, retail industry and leading brands through a full-data quantification and multi-dimensional index method, reflecting the development of the industry.

SIP Index Pharmaceutical Industry Development Index Industry Investment, Revenue Level, Profit Level, Export Trade

In the third quarter, the sales revenue and profit of the pharmaceutical industry declined significantly, and the development of chemical preparations and proprietary Chinese medicine manufacturing was insufficient.
According to the statistics of the Ministry of Industry and Information Technology, the national pharmaceutical industry revenue in the third quarter of 2021 was 694.
8 billion yuan, a simultaneous increase of 13%, but compared with 2 The quarterly decrease of 3.
3%, and the scale decreased by 23.
6 billion yuan; in the third quarter of 2021, the total profit of the pharmaceutical industry dropped from 181.
7 billion yuan in the second quarter to 149 billion yuan, a decrease of 18.
0%, and the decline was relatively large; but compared with the same period last year, the pharmaceutical industry.
Total industrial profits increased by 67%, mainly due to the new crown vaccine
.

According to statistics from the General Administration of Customs, in 2021, the export volume of China's pharmaceuticals (including medicinal materials and medicines) will reach 1.

In the third quarter, the sales revenue and profit of the pharmaceutical industry declined significantly, and the development momentum of chemical preparations and Chinese patent medicine manufacturing was insufficient.

Source of data: Zhongkang CMH In recent years, domestic biopharmaceutical companies have intensively landed in the capital market.
With the support of the continuous reform of the national new drug review and approval system, China's biopharmaceutical industry has seen considerable innovation and development.
With the accelerated rise of domestic innovative drugs, industry investment maintain a high degree of prosperity
.

Among the six major sub-sectors of the pharmaceutical industry, the chemical preparation manufacturing industry contributed 29.

Figure 3: 2019Q1-2021Q3 Profit Contribution of the Six Sub-sectors of the Pharmaceutical Industry to the Pharmaceutical Industry

Data source: Zhongkang CMH pharmaceutical industry development index fluctuates, and the third quarter ushered in a cyclical inflection point, but the overall is still rising steadily The pharmaceutical industry development index in the third quarter of 2021 was 128.
0, down 6.
9% from the second quarter, but year-on-year in March 2020.
The quarterly increase was 16.
6%; in general, since the first quarter of 2020, although the development of the industry's prosperity has fluctuated, the overall level has risen, showing a steady development trend
.

The manufacturing of biopharmaceuticals and the manufacturing of sanitary materials and medical supplies has been the main engine for the development of the pharmaceutical industry since the second quarter of 2020

The pharmaceutical industry development index fluctuates, and the third quarter ushered in a cyclical inflection point, but the overall growth is still steady

Data source: Zhongkang CMH

Note: Using the fixed-base index algorithm, based on the average value of 2018, weighted modeling is carried out from the four dimensions of industry investment, revenue level, profitability level, and export trade, and the pharmaceutical industry development index is calculated to obtain biological drugs, health materials and medical supplies.
The manufacturing industry has made outstanding contributions to the development of the pharmaceutical industry.
Among the six major sub-sectors of the pharmaceutical industry, the biopharmaceutical manufacturing industry is in a benign development stage, and the industry prosperity index is 346.
5, which is much higher than the benchmark level; The vaccination rate has increased rapidly, the vaccine market tends to be saturated, and the biopharmaceutical manufacturing industry index has risen and fallen, down 14.
6% compared to the previous quarter
.

With the normalization of epidemic prevention and control and the changes in the environment of repeated outbreaks of epidemics in many places in China, sales of epidemic-related products, such as nucleic acid testing, protective equipment, etc.

Biopharmaceuticals, sanitary materials and medical supplies have made outstanding contributions to the development of the pharmaceutical industry

Affected by the normalization of drug procurement and consistency evaluation, the revenue and profitability of some drug varieties are still declining.
The chemical drug API manufacturing index is 108.
6 in the third quarter of 2021, and the industry boom has dropped to the same period in 2020.
level, but still slightly higher than the chemical preparation manufacturing industry
.

Relying on cost advantages, API companies have extended to preparation production, giving preparation products more room for price reduction, intensifying price competition in the industry, and leading to a decline in industry revenue and profits

Data source: Zhongkang CMH

Note: Using the fixed-base index algorithm, the overall growth of the pharmaceutical industry is based on the average value of 2018.